Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
fda
5
×
life sciences
5
×
national blog main
biotech
boston blog main
boston top stories
national
national top stories
new york blog main
new york top stories
san francisco blog main
san francisco top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
medicare
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
bristol-myers squibb
drug price
immunotherapy
jim greenwood
merck
regeneron pharmaceuticals
trump administration
abbvie
abeona therapeutics
ac immune
acquisition
What
industry
5
×
bio
policy
price
roundup
scalps
administration
adversity
american
angry
anti
arrival
based
beats
benefited
best
biopharma
biotech
car
celgene
cold
colleagues
companies
continue
crash
days
dealing
debate
despite
discussed
drug
early
exact
exome
fear
flu
forecasts
government
hasn’t
health
Language
unset
Current search:
fda
×
industry
×
" life sciences "
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
5 years ago
Bio Roundup: Trump’s Scalps, Policy Pressure, NASH Crash & More
@xconomy.com
5 years ago
Losing “Scalps”? Despite Pharma Fear, A Split on Trump Rx-Price Plans
@xconomy.com
5 years ago
Bio Roundup: $74B for Celgene, Two CAR-T Tales, Ready for SF & More
@xconomy.com
6 years ago
Exact Sciences Beats Quarterly Forecasts, Sending Its Stock Price Up
